GB9712370D0 - Therapeutic systems - Google Patents

Therapeutic systems

Info

Publication number
GB9712370D0
GB9712370D0 GBGB9712370.7A GB9712370A GB9712370D0 GB 9712370 D0 GB9712370 D0 GB 9712370D0 GB 9712370 A GB9712370 A GB 9712370A GB 9712370 D0 GB9712370 D0 GB 9712370D0
Authority
GB
United Kingdom
Prior art keywords
nqo2
fragment
fusion
variant
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9712370.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aepact Ltd
Original Assignee
Aepact Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aepact Ltd filed Critical Aepact Ltd
Priority to GBGB9712370.7A priority Critical patent/GB9712370D0/en
Publication of GB9712370D0 publication Critical patent/GB9712370D0/en
Priority to JP50395399A priority patent/JP4272263B2/ja
Priority to DK98929555T priority patent/DK0988059T3/da
Priority to EP04076964A priority patent/EP1468698A3/en
Priority to GB0126082A priority patent/GB2365338B/en
Priority to GB9928237A priority patent/GB2341605B/en
Priority to DE69832702T priority patent/DE69832702T2/de
Priority to EP98929555A priority patent/EP0988059B8/en
Priority to CA002292608A priority patent/CA2292608A1/en
Priority to PCT/GB1998/001731 priority patent/WO1998057662A2/en
Priority to AT98929555T priority patent/ATE311905T1/de
Priority to US09/445,865 priority patent/US6867231B1/en
Priority to ES98929555T priority patent/ES2257810T3/es
Priority to HK00102240.4A priority patent/HK1023069B/xx
Priority to HK02103701.2A priority patent/HK1041824B/zh
Priority to US10/099,830 priority patent/US7138122B2/en
Priority to CY20061100305T priority patent/CY1105424T1/el
Priority to US11/558,042 priority patent/US20070166296A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB9712370.7A 1997-06-14 1997-06-14 Therapeutic systems Pending GB9712370D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB9712370.7A GB9712370D0 (en) 1997-06-14 1997-06-14 Therapeutic systems
HK00102240.4A HK1023069B (en) 1997-06-14 1998-06-15 Therapeutic systems
CA002292608A CA2292608A1 (en) 1997-06-14 1998-06-15 Therapeutic systems for activation prodrugs
AT98929555T ATE311905T1 (de) 1997-06-14 1998-06-15 Menschliche chinon reduktase konjugate für adept und gdept
EP04076964A EP1468698A3 (en) 1997-06-14 1998-06-15 Human quinone reductase 2 conjugates for adept and gdept
GB0126082A GB2365338B (en) 1997-06-14 1998-06-15 Therapeutic systems
GB9928237A GB2341605B (en) 1997-06-14 1998-06-15 Therapeutic systems
DE69832702T DE69832702T2 (de) 1997-06-14 1998-06-15 Menschliche chinon reduktase konjugate für adept und gdept
EP98929555A EP0988059B8 (en) 1997-06-14 1998-06-15 Human quinone reductase 2 conjugates for adept and gdept
JP50395399A JP4272263B2 (ja) 1997-06-14 1998-06-15 治療システム
PCT/GB1998/001731 WO1998057662A2 (en) 1997-06-14 1998-06-15 Therapeutic systems
DK98929555T DK0988059T3 (da) 1997-06-14 1998-06-15 Humane quinonreduktase-2-konjugater til ADEPT og GDEPT
US09/445,865 US6867231B1 (en) 1997-06-14 1998-06-15 Therapeutic systems
ES98929555T ES2257810T3 (es) 1997-06-14 1998-06-15 Conjugados de quinona reductasa humana para adept y gdept.
HK02103701.2A HK1041824B (zh) 1997-06-14 2000-04-13 治療系統
US10/099,830 US7138122B2 (en) 1997-06-14 2002-03-13 Therapeutic systems
CY20061100305T CY1105424T1 (el) 1997-06-14 2006-03-07 Συζυγη ανθρωπινης ρεδουκτασης 2 κινονης για adept και gdept
US11/558,042 US20070166296A1 (en) 1997-06-14 2006-11-09 Therapeutic Systems

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712370.7A GB9712370D0 (en) 1997-06-14 1997-06-14 Therapeutic systems

Publications (1)

Publication Number Publication Date
GB9712370D0 true GB9712370D0 (en) 1997-08-13

Family

ID=10814135

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9712370.7A Pending GB9712370D0 (en) 1997-06-14 1997-06-14 Therapeutic systems
GB9928237A Expired - Fee Related GB2341605B (en) 1997-06-14 1998-06-15 Therapeutic systems

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB9928237A Expired - Fee Related GB2341605B (en) 1997-06-14 1998-06-15 Therapeutic systems

Country Status (12)

Country Link
US (3) US6867231B1 (enExample)
EP (2) EP1468698A3 (enExample)
JP (1) JP4272263B2 (enExample)
AT (1) ATE311905T1 (enExample)
CA (1) CA2292608A1 (enExample)
CY (1) CY1105424T1 (enExample)
DE (1) DE69832702T2 (enExample)
DK (1) DK0988059T3 (enExample)
ES (1) ES2257810T3 (enExample)
GB (2) GB9712370D0 (enExample)
HK (1) HK1041824B (enExample)
WO (1) WO1998057662A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9712370D0 (en) * 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB9903019D0 (en) * 1999-02-10 1999-03-31 Microbiological Res Authority Nitroreductase enzymes
EP1210358A4 (en) * 1999-08-13 2005-01-05 Univ Brandeis PROOF OF NUCLEIC ACIDS
CN1315529A (zh) * 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人醌蛋白还原酶9和编码这种多肽的多核苷酸
WO2003025128A2 (en) * 2001-09-14 2003-03-27 Duke University Quinone reductase 2 and aldehyde dehydrogenase as therapeutic targets
GB0328314D0 (en) * 2003-12-05 2004-01-07 Univ Bath Therapeutics
EP1723227A4 (en) * 2004-02-10 2007-09-19 Dartmouth College NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
US8114626B2 (en) * 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
EP2805719A1 (en) * 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
GB2442202A (en) 2006-09-30 2008-04-02 Morvus Technology Ltd Vermin poison
CA2956163C (en) 2014-07-24 2023-01-10 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
ES2963057T3 (es) 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida
NZ735411A (en) * 2015-03-16 2021-07-30 Chromadex Inc Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof
WO2017011788A1 (en) * 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
NZ803738A (en) 2016-11-11 2024-05-31 Chromadex Inc Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
EP3554285A4 (en) 2016-11-29 2021-01-20 University of Iowa Research Foundation USE OF NAD PRECURSORS TO IMPROVE THE HEALTH OF MOTHER AND / OR OFFspring
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US440859A (en) * 1890-11-18 Wire-rope machine
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
JPS5460386A (en) * 1977-10-20 1979-05-15 Fuji Photo Film Co Ltd Photopolymerizable composition
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US5087618A (en) * 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
JPS60184252A (ja) * 1984-03-02 1985-09-19 Canon Inc 電子写真感光体
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
GB8615701D0 (en) 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
NZ225599A (en) 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
ATE135045T1 (de) 1988-07-23 1996-03-15 Delta Biotechnology Ltd Sekretorische leader-sequenzen
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
GB8929097D0 (en) 1989-12-22 1990-02-28 Imp Cancer Res Tech Mucin nucleotides
GB9001641D0 (en) 1990-01-24 1990-03-21 Imp Cancer Res Tech Compounds
JP4115514B2 (ja) 1991-10-23 2008-07-09 キャンサー・リサーチ・キヤンペーン・テクノロジー・リミテツド Ｃｂ １９５４およびその類似体を細胞障害性の形態に還元するための細菌のニトロリダクターゼ
GB9200417D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
GB9200415D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
GB9323008D0 (en) * 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
GB9516943D0 (en) * 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
GB9524942D0 (en) 1995-12-06 1996-02-07 Aepact Ltd Drug therapy
EP0869818A1 (en) 1995-12-29 1998-10-14 AEPACT Limited Cytotoxic agents
WO1998022577A1 (en) 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
GB9624993D0 (en) 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
GB9712370D0 (en) * 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems

Also Published As

Publication number Publication date
EP1468698A2 (en) 2004-10-20
WO1998057662A2 (en) 1998-12-23
JP4272263B2 (ja) 2009-06-03
WO1998057662A3 (en) 1999-08-12
DK0988059T3 (da) 2006-01-23
DE69832702T2 (de) 2006-08-10
US20070166296A1 (en) 2007-07-19
JP2002511754A (ja) 2002-04-16
EP0988059A2 (en) 2000-03-29
US6867231B1 (en) 2005-03-15
EP0988059B8 (en) 2006-03-01
HK1023069A1 (en) 2000-09-01
EP1468698A3 (en) 2005-03-23
US7138122B2 (en) 2006-11-21
GB2341605B (en) 2002-02-20
HK1041824A1 (en) 2002-07-26
GB2341605A (en) 2000-03-22
ATE311905T1 (de) 2005-12-15
GB9928237D0 (en) 2000-01-26
US20030086933A1 (en) 2003-05-08
GB2341605A8 (en) 2000-03-28
CY1105424T1 (el) 2010-04-28
EP0988059B1 (en) 2005-12-07
DE69832702D1 (de) 2006-01-12
HK1041824B (zh) 2002-11-15
ES2257810T3 (es) 2006-08-01
CA2292608A1 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
GB2341605B (en) Therapeutic systems
BE2018C038I2 (enExample)
TW225532B (enExample)
AU1922101A (en) Human fgf-21 gene and gene expression products
EP0972517A3 (en) Use of 1,2,4-benzotriazine oxides for the preparation of a medicament for the treatment of tumours
ES2043890T3 (es) Nuevo uso medico.
CA2413736A1 (en) Thorium or actinium radionuclides for endoradionuclide therapy
IL141494A0 (en) Stable hypoxia inducible factor-1 alpha and method of use
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
AU2047692A (en) Therapeutic amides
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
EP0210351A3 (en) Use of porphyrin derivatives in the detection and treatment of tumours
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
DK0951553T3 (da) Adenovirus-E4-proteiner til induktion af celledød
MX9200413A (es) Composicion farmaceutica para el tratamiento y/o diagnostico de tumores de tejido blando.
EP0484112A3 (en) Use of lithium in the treatment or prophylaxis of molluscum contagiosum
AU3260093A (en) Use of creatine phosphate or phosphoenolpyruvic acid for the treatment of tumours
ATE251640T1 (de) Neues chondrozytprotein
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog
HU9200025D0 (en) Medical preparations for treating depression
HU9301719D0 (en) Medical preparatives for treatment of b-cell tumours
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
MXPA94003453A (es) Metodo y composicion para el tratamiento de pacientes con hepatitis b que tienen descompensacion hepatica.